drugset
drugset / Trial / NCT03334084

A Study to Compare the PK, PD and Safety and Tolerability of a SC With an IV Formulation of ARGX-113 in Healthy Male Subjects

NCT03334084 ↗

Phase 1 Completed 40 enrolled argenx
RandomizedParallel-groupOpen-labelBasic science

Summary

The study is a Randomized, Open-label, Parallel Group Study to Compare the Pharmacokinetics, Pharmacodynamics and Safety and Tolerability of a Subcutaneous Formulation With an Intravenous Formulation of ARGX-113 in Healthy Male Subjects

Timeline

Start
2017-10-11
Primary completion
2018-09-19
Completion
2018-09-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Efgartigimod Alfa Protein / enzyme biologic — Intravenous

Indications

No indication recorded.